Health Trials

Neoplasms, Endometrial

5

Review clinical trials related to Neoplasms, Endometrial. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

The purpose of this study is to see how well GSK5733584 in combination with standard treatment of choice works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared to current standard of care. The study will also assess whether drug combination is safe and tolerated well by participants compared to the usual care and will help us better understand its impact on Health-Related Quality of Life of participants.

Participants needed: 610
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: GlaxoSmithKlineUpdated: Jul 15, 2026
Eligibility criteria

Is at least 18 years of age and the legal age of consent in the jurisdiction in... [+13]

Mesenchymal tumors of the uterus (uterine sarcomas) and neuroendocrine uterine c... [+16]

Read more
Status: Recruiting

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: GlaxoSmithKlineUpdated: Jul 15, 2026Locations: 18
Eligibility criteria

Is at least 18 years of age and the legal age of consent in the jurisdiction in... [+22]

Mesenchymal tumors of the uterus (uterine sarcomas) and neuroendocrine uterine c... [+31]

Read more
Status: Not yet recruiting

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).

Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: FemaleType: InterventionalSponsor: GlaxoSmithKlineUpdated: Jun 17, 2026
Eligibility criteria

Participant with greater than or equals to (>=) 18 years of age, at the time of... [+7]

Participant has had greater than (>) 1 recurrence of endometrial cancer. [+17]

Read more
Status: Recruiting

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: GlaxoSmithKlineUpdated: Dec 22, 2025Locations: 1
Eligibility criteria

Participant has histologically or cytologically proven EC with recurrent or adva... [+8]

Participant has a concomitant malignancy, or participant has a prior non-endomet... [+12]

Read more
Status: Not yet recruiting

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: FemaleType: InterventionalSponsor: GlaxoSmithKlineUpdated: Jul 8, 2025
Eligibility criteria

Participants ≥18 years of age, at the time of signing the informed consent. [+5]

Known active hepatic disease, End-Stage Renal Disease (ESRD) or known case of se... [+7]

Read more